ACRSAclaris Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Aclaris Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACRSEsta | $784M#3 | — | 6.3x#7 | 100.2x#5 | -58.2%#5 | 50.8%#4 | -975.9%#5 | -52.1%#7 | -65.8%#4 | 3#3 | 190.2%#1 | — |
| CYRX | $836M#1 | — | 1.7x#1 | 4.7x#3 | 12.4%#4 | 168.2%#3 | -20.9%#3 | 16.0%#4 | -16.5%#3 | 4#1 | 83.2%#2 | — |
| RIGL | $831M#2 | 2.6x#1 | 2.0x#2 | 2.8x#2 | 64.1%#2 | 1999.1%#1 | 42.6%#1 | 86.3%#1 | 30.6%#2 | — | 27.0%#4 | — |
| DSGN | $783M#4 | — | 3.9x#5 | — | — | -40.7%#8 | — | -34.6%#6 | — | — | — | — |
| COLL | $723M#5 | 17.5x#3 | 2.3x#3 | 0.9x#1 | 23.6%#3 | -8.7%#6 | 23.0%#2 | 20.2%#3 | 62.0%#1 | 4#1 | -37.7%#5 | — |
| NVCT | $712M#6 | — | 78.4x#8 | — | — | -39.2%#7 | — | -291.1%#8 | — | — | — | — |
| ZVRA | $701M#7 | 12.7x#2 | 3.2x#4 | 6.6x#4 | 350.9%#1 | 178.9%#2 | -59.1%#4 | 38.2%#2 | — | — | — | — |
| MNPR | $679M#8 | — | 5.2x#6 | — | — | 12.0%#5 | — | -10.5%#5 | — | — | 77.8%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice